Alumis Secures $300 Million in Upsized Public Offering—What Does This Mean for Its Immunology Pipeline?
Market Chameleon (Thu, 8-Jan 7:53 AM)
Alumis Launches $175M Public Offering: What Does the Move Signal for Investors?
Market Chameleon (Wed, 7-Jan 10:34 AM)
Alumis Announces Phase 3 ONWARD Topline Data Call—Key Catalysts Ahead for Psoriasis Treatment Pipeline
Market Chameleon (Tue, 6-Jan 9:52 AM)
Alumis' Envudeucitinib Achieves Top Results in Phase 3 Trials: Over 65% of Psoriasis Patients Attain Near-Complete Skin Clearance
Market Chameleon (Tue, 6-Jan 7:06 AM)
